• 180+

    The UK’s most active investor in UK university spin-outs

  • £500M

    Over £500m raised; invested into over 180 companies

  • £150M

    Cash returned to investors via exits

  • £1.1Bn

    Part of FTSE 250 sector specialist group with £1.1bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Parkwalk Open Funds

Parkwalk offer early-stage investment funds, investing in high-growth, knowledge intensive companies spun out of the UK’s world-leading universities and providing tax benefits under the Enterprise Investment Scheme.

Opportunities EIS Fund

Our evergreen EIS Fund, investing in EIS-qualifying hard science and deep tech companies spun out of universities across the UK.
Learn More

University of Cambridge Enterprise Fund X

Our UCEF X invests in high-growth, IP-rich technologies founded at the University of Cambridge.
Learn More

Parkwalk Knowledge Intensive EIS Fund IV

The Parkwalk Knowledge Intensive EIS Funds mirror the investment strategy of our flagship Opportunities EIS Fund.
Learn more

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Lucy Allen
Cassie Doherty
Steve Churchhouse
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Phoremost

PhoreMost has developed a next-generation phenotypic screening platform called ‘Site-Seeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.

Zomp

Zomp is a University of Cambridge spin-out which is building the world’s first 3D imaging cytometer and cell sorter. This new 3D imaging cytometry will revolutionise cell sorting and analysis, enabling the accurate measurement and sorting of single cells at high throughput based on observable characteristics.

Definigen

DefiniGEN provides human cells to the life science and drug discovery sectors for use in lead optimization and toxicity programmes. DefiniGEN’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.

View Portfolio